Fig. 6.

Event rates (a) and hazard ratios (b, c) for stroke or systemic embolism (a, b) and major bleedings (b, c) in patients ≥ 75 years of age in ARISTOTLE and ENGAGE-AF depending on the presence or absence of study-specific dose reduction criteria. HR, hazard ratio; NOAC, non-vitamin K oral anticoagulants; SSE, stroke or systemic embolism; VKA, vitamin K antagonist. Definition of major bleeding according to study criteria as well as dosing regimens is given for all studies in the main text. * indicates a group of patients qualifying for the study-specific dose reduction criteria who were treated with warfarin